Omnicell shares have risen 51.6% over the past year, outperforming an industry decline of 21.2% and the S&P 500's 23.2% gain. The company holds a Zacks Rank #3, or Hold, with a market capitalization of $1.96 billion and an earnings yield of 4.7%. Omnicell continues to advance its autonomous pharmacy vision and expand its SaaS and Expert Services portfolio through acquisitions and new platform launches, though escalating expenses, including an estimated $12 million in tariff-related costs for 2026, and intense competition may pressure margins. The Zacks Consensus Estimate for 2026 earnings per share has risen to $1.97 over the past 30 days, with revenues projected at $1.24 billion, a 4.9% increase from the prior year.
Omnicell IncOmnicell is advancing its autonomous pharmacy vision and expanding SaaS/Expert Services portfolio through acquisitions and new platform launches.
Phibro Animal Health Corporation
Globus Medical
Integra LifeSciences Holdings